Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
A patient with myelofibrosis with myeloid metaplasia displaying the V617F mutation of the JAK2 gene was given an allogeneic stem cell transplantation using a reduced-intensity conditioning regimen. The patient engrafted, and as he became a chimera, the expression of the V617F mutation of the JAK2 gene decreased progressively until its disappearance. Accordingly, the concept of "molecular remission" of the myelofibrosis with myeloid metaplasia could be entertained and added to the categories of response to treatment which have been recently described.
Ruiz-Argüelles
Guillermo J
GJ
Centro de Hematología y Medicina Interna de Puebla, Puebla, México. gruiz1@clinicaruiz.com
Garcés-Eisele
Javier
J
Reyes-Núñez
Virginia
V
Ruiz-Delgado
Guillermo J
GJ
Rosillo
Carlos
C
Camoriano
John K
JK
D015415:Biomarkers; D006801:Humans; D053614:Janus Kinase 2 / Q000097:blood / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000097:blood / Q000235:genetics*; D036102:Peripheral Blood Stem Cell Transplantation; D017354:Point Mutation; D055728:Primary Myelofibrosis / Q000097:blood / Q000235:genetics* / Q000601:surgery; D012074:Remission Induction; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D015415:Biomarkers; D009363:Neoplasm Proteins; C507924:JAK2 protein, human; D053614:Janus Kinase 2